Advanced Medical Solutions ((GB:AMS)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Advanced Medical Solutions is conducting a study titled ‘Long-Term Safety and Efficacy Evaluation of Seal-G and Seal-G MIST Surgical Sealants for Anastomosis Protection in Colon Surgery.’ The study aims to assess the long-term safety and effectiveness of Seal-G/MIST surgical sealants in reducing postoperative complications in colon anastomosis surgeries, such as leaks and obstructions, over a period exceeding 12 months.
Intervention/Treatment: The study focuses on the Seal-G and Seal-G MIST surgical sealants, designed to provide a protective barrier over the anastomosis site, potentially reducing the risk of complications following colon surgery.
Study Design: This observational study employs a cohort model with a retrospective time perspective. It compares patients who received the Seal-G/MIST treatment during a previous study with a control group who underwent standard procedures without the sealant.
Study Timeline: The study is not yet recruiting, with the initial submission date on July 28, 2025. This marks the beginning of the study’s timeline, with further updates expected as the study progresses.
Market Implications: The continuation of this study could significantly influence Advanced Medical Solutions’ stock performance and investor confidence. Positive long-term results may enhance the company’s competitive position in the surgical sealant market, potentially impacting industry dynamics.
The study is ongoing, with more details available on the ClinicalTrials portal.